A phase Ia/b study to to evaluate the safety, efficacy, and pharmacokinetics of GTA182 across multiple ascending doses, as a monotherapy and in combination with standard of care therapy, in adults with advanced MTAP null solid tumors
Latest Information Update: 15 Jan 2025
Price :
$35 *
At a glance
- Drugs GTA-182 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- 15 Jan 2025 New trial record
- 08 Jan 2025 First patient has been dosed.
- 14 Oct 2024 According to Apeiron media release,the company receive the IND Clearance from China National Medical Products Administration (NMPA),for the treatment of MTAP-null solid tumors.Also the company plans to file an Investigational New Drug (IND) application with the US FDA for GTA182 in 2025.